BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15965487)

  • 1. BRCA1 participates in DNA decatenation.
    Lou Z; Minter-Dykhouse K; Chen J
    Nat Struct Mol Biol; 2005 Jul; 12(7):589-93. PubMed ID: 15965487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
    Sakaguchi A; Kikuchi A
    J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cyclins A, E and topoisomerase II alpha correlates with centrosome amplification and genomic instability and influences the reliability of cytometric S-phase determination.
    Kronenwett U; Castro J; Roblick UJ; Fujioka K; Ostring C; Faridmoghaddam F; Laytragoon-Lewin N; Tribukait B; Auer G
    BMC Cell Biol; 2003 Jul; 4():8. PubMed ID: 12875657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S;
    Cancer Lett; 2008 Jun; 264(1):44-53. PubMed ID: 18280644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress.
    Shinagawa H; Miki Y; Yoshida K
    Antioxid Redox Signal; 2008 May; 10(5):939-49. PubMed ID: 18162055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
    Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
    Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
    Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fbxo28 promotes mitotic progression and regulates topoisomerase IIα-dependent DNA decatenation.
    Kratz AS; Richter KT; Schlosser YT; Schmitt M; Shumilov A; Delecluse HJ; Hoffmann I
    Cell Cycle; 2016 Dec; 15(24):3419-3431. PubMed ID: 27754753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
    Gardner L; Malik R; Shimizu Y; Mullins N; ElShamy WM
    Breast Cancer Res; 2011 May; 13(3):R53. PubMed ID: 21595939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line.
    Toyoda E; Kurosawa A; Kamekawa H; Adachi N
    Biochem Biophys Res Commun; 2009 May; 382(3):492-6. PubMed ID: 19285952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
    Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
    Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
    Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH
    Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
    Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
    Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.
    Hasinoff BB; Wu X; Krokhin OV; Ens W; Standing KG; Nitiss JL; Sivaram T; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Mol Pharmacol; 2005 Mar; 67(3):937-47. PubMed ID: 15602006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha.
    Jonstrup AT; Thomsen T; Wang Y; Knudsen BR; Koch J; Andersen AH
    Nucleic Acids Res; 2008 Nov; 36(19):6165-74. PubMed ID: 18824478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranucleolar localization of DNA topoisomerase IIalpha is a distinctive feature of necrotic, but not of apoptotic, Jurkat T-cells.
    Falcieri E; Burattini S; Bortul R; Luchetti F; Tabellini G; Tazzari PL; Cappellini A; Cocco L; Martelli AM
    Microsc Res Tech; 2003 Oct; 62(3):192-200. PubMed ID: 14506684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
    Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
    Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
    Yun J; Zhong Q; Kwak JY; Lee WH
    Oncogene; 2005 Jun; 24(25):4009-16. PubMed ID: 15782115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
    Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
    Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.